nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ABCB1—lung cancer	0.16	1	CbGaD
Mefloquine—ACHE—Irinotecan—lung cancer	0.0681	0.137	CbGbCtD
Mefloquine—CYP19A1—Paclitaxel—lung cancer	0.0499	0.1	CbGbCtD
Mefloquine—BCHE—Irinotecan—lung cancer	0.041	0.0825	CbGbCtD
Mefloquine—BCHE—Cisplatin—lung cancer	0.0335	0.0673	CbGbCtD
Mefloquine—ABCB1—Topotecan—lung cancer	0.0213	0.0429	CbGbCtD
Mefloquine—ABCB1—Gefitinib—lung cancer	0.0195	0.0392	CbGbCtD
Mefloquine—CYP2D6—Gefitinib—lung cancer	0.0184	0.037	CbGbCtD
Mefloquine—ABCB1—Vinorelbine—lung cancer	0.015	0.0302	CbGbCtD
Mefloquine—CYP2D6—Vinorelbine—lung cancer	0.0142	0.0285	CbGbCtD
Mefloquine—CYP3A4—Topotecan—lung cancer	0.0128	0.0257	CbGbCtD
Mefloquine—ABCB1—Crizotinib—lung cancer	0.012	0.024	CbGbCtD
Mefloquine—CYP3A4—Gefitinib—lung cancer	0.0117	0.0235	CbGbCtD
Mefloquine—ABCB1—Gemcitabine—lung cancer	0.0117	0.0235	CbGbCtD
Mefloquine—ABCB1—Erlotinib—lung cancer	0.0115	0.0232	CbGbCtD
Mefloquine—CYP3A4—Teniposide—lung cancer	0.0113	0.0228	CbGbCtD
Mefloquine—CYP2D6—Erlotinib—lung cancer	0.0109	0.0219	CbGbCtD
Mefloquine—ABCB1—Paclitaxel—lung cancer	0.0106	0.0212	CbGbCtD
Mefloquine—ABCB1—Irinotecan—lung cancer	0.0104	0.0209	CbGbCtD
Mefloquine—ABCB1—Vinblastine—lung cancer	0.00926	0.0186	CbGbCtD
Mefloquine—CYP3A4—Vinorelbine—lung cancer	0.009	0.0181	CbGbCtD
Mefloquine—CYP2D6—Vinblastine—lung cancer	0.00873	0.0175	CbGbCtD
Mefloquine—ABCB1—Cisplatin—lung cancer	0.00849	0.0171	CbGbCtD
Mefloquine—ABCB1—Etoposide—lung cancer	0.00834	0.0168	CbGbCtD
Mefloquine—ABCB1—Docetaxel—lung cancer	0.00763	0.0154	CbGbCtD
Mefloquine—CYP3A4—Crizotinib—lung cancer	0.00716	0.0144	CbGbCtD
Mefloquine—CYP3A4—Erlotinib—lung cancer	0.00691	0.0139	CbGbCtD
Mefloquine—BCHE—diaphragm—lung cancer	0.00689	0.185	CbGeAlD
Mefloquine—CYP3A4—Paclitaxel—lung cancer	0.00633	0.0127	CbGbCtD
Mefloquine—CYP3A4—Irinotecan—lung cancer	0.00624	0.0126	CbGbCtD
Mefloquine—ABCB1—Doxorubicin—lung cancer	0.00569	0.0114	CbGbCtD
Mefloquine—CYP3A4—Vinblastine—lung cancer	0.00555	0.0112	CbGbCtD
Mefloquine—ABCB1—Methotrexate—lung cancer	0.00551	0.0111	CbGbCtD
Mefloquine—CYP2D6—Doxorubicin—lung cancer	0.00536	0.0108	CbGbCtD
Mefloquine—CYP3A4—Etoposide—lung cancer	0.005	0.0101	CbGbCtD
Mefloquine—CYP3A4—Docetaxel—lung cancer	0.00457	0.0092	CbGbCtD
Mefloquine—HBA1—respiratory system—lung cancer	0.0039	0.105	CbGeAlD
Mefloquine—HBA2—respiratory system—lung cancer	0.00358	0.0962	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—lung cancer	0.00341	0.00686	CbGbCtD
Mefloquine—HBA2—epithelium—lung cancer	0.00299	0.0804	CbGeAlD
Mefloquine—HBA1—bone marrow—lung cancer	0.00229	0.0614	CbGeAlD
Mefloquine—HBA2—bone marrow—lung cancer	0.0021	0.0564	CbGeAlD
Mefloquine—HBA1—lung—lung cancer	0.00207	0.0557	CbGeAlD
Mefloquine—HBA2—lung—lung cancer	0.0019	0.0511	CbGeAlD
Mefloquine—HBA1—lymph node—lung cancer	0.00142	0.0381	CbGeAlD
Mefloquine—HBA2—lymph node—lung cancer	0.0013	0.0349	CbGeAlD
Mefloquine—ADORA1—cardiac atrium—lung cancer	0.00112	0.03	CbGeAlD
Mefloquine—ADORA1—lung—lung cancer	0.000855	0.023	CbGeAlD
Mefloquine—BCHE—respiratory system—lung cancer	0.000787	0.0211	CbGeAlD
Mefloquine—BCHE—bronchus—lung cancer	0.000647	0.0174	CbGeAlD
Mefloquine—ADORA1—lymph node—lung cancer	0.000585	0.0157	CbGeAlD
Mefloquine—BCHE—trachea—lung cancer	0.000581	0.0156	CbGeAlD
Mefloquine—ACHE—lymph node—lung cancer	0.000581	0.0156	CbGeAlD
Mefloquine—BCHE—cardiac atrium—lung cancer	0.000546	0.0147	CbGeAlD
Mefloquine—BCHE—bone marrow—lung cancer	0.000461	0.0124	CbGeAlD
Mefloquine—BCHE—lung—lung cancer	0.000418	0.0112	CbGeAlD
Mefloquine—CYP19A1—lymph node—lung cancer	0.000397	0.0107	CbGeAlD
Mefloquine—ABCB1—respiratory system—lung cancer	0.000375	0.0101	CbGeAlD
Mefloquine—ABCB1—epithelium—lung cancer	0.000313	0.00841	CbGeAlD
Mefloquine—BCHE—lymph node—lung cancer	0.000286	0.00767	CbGeAlD
Mefloquine—ABCB1—trachea—lung cancer	0.000277	0.00744	CbGeAlD
Mefloquine—ABCB1—bone marrow—lung cancer	0.00022	0.0059	CbGeAlD
Mefloquine—ABCB1—lung—lung cancer	0.000199	0.00535	CbGeAlD
Mefloquine—ABCB1—lymph node—lung cancer	0.000136	0.00366	CbGeAlD
Mefloquine—Renal failure—Methotrexate—lung cancer	9.57e-05	0.00051	CcSEcCtD
Mefloquine—Rash—Vinorelbine—lung cancer	9.53e-05	0.000508	CcSEcCtD
Mefloquine—Dermatitis—Vinorelbine—lung cancer	9.52e-05	0.000508	CcSEcCtD
Mefloquine—Hypotension—Paclitaxel—lung cancer	9.5e-05	0.000506	CcSEcCtD
Mefloquine—Headache—Vinorelbine—lung cancer	9.47e-05	0.000505	CcSEcCtD
Mefloquine—Syncope—Docetaxel—lung cancer	9.47e-05	0.000505	CcSEcCtD
Mefloquine—Leukopenia—Docetaxel—lung cancer	9.45e-05	0.000504	CcSEcCtD
Mefloquine—Sweating—Methotrexate—lung cancer	9.33e-05	0.000498	CcSEcCtD
Mefloquine—Palpitations—Docetaxel—lung cancer	9.33e-05	0.000497	CcSEcCtD
Mefloquine—Feeling abnormal—Cisplatin—lung cancer	9.33e-05	0.000497	CcSEcCtD
Mefloquine—Paraesthesia—Etoposide—lung cancer	9.31e-05	0.000496	CcSEcCtD
Mefloquine—Loss of consciousness—Docetaxel—lung cancer	9.28e-05	0.000495	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Paclitaxel—lung cancer	9.26e-05	0.000494	CcSEcCtD
Mefloquine—Dyspnoea—Etoposide—lung cancer	9.24e-05	0.000493	CcSEcCtD
Mefloquine—Somnolence—Etoposide—lung cancer	9.22e-05	0.000491	CcSEcCtD
Mefloquine—Hepatobiliary disease—Methotrexate—lung cancer	9.21e-05	0.000491	CcSEcCtD
Mefloquine—Insomnia—Paclitaxel—lung cancer	9.19e-05	0.00049	CcSEcCtD
Mefloquine—Hypersensitivity—Irinotecan—lung cancer	9.18e-05	0.00049	CcSEcCtD
Mefloquine—Convulsion—Docetaxel—lung cancer	9.15e-05	0.000488	CcSEcCtD
Mefloquine—Paraesthesia—Paclitaxel—lung cancer	9.13e-05	0.000487	CcSEcCtD
Mefloquine—Hypertension—Docetaxel—lung cancer	9.11e-05	0.000486	CcSEcCtD
Mefloquine—Agranulocytosis—Methotrexate—lung cancer	9.09e-05	0.000484	CcSEcCtD
Mefloquine—Dyspnoea—Paclitaxel—lung cancer	9.06e-05	0.000483	CcSEcCtD
Mefloquine—Somnolence—Paclitaxel—lung cancer	9.04e-05	0.000482	CcSEcCtD
Mefloquine—Decreased appetite—Etoposide—lung cancer	9.01e-05	0.00048	CcSEcCtD
Mefloquine—Chest pain—Docetaxel—lung cancer	8.99e-05	0.000479	CcSEcCtD
Mefloquine—Myalgia—Docetaxel—lung cancer	8.99e-05	0.000479	CcSEcCtD
Mefloquine—Arthralgia—Docetaxel—lung cancer	8.99e-05	0.000479	CcSEcCtD
Mefloquine—Nausea—Vinorelbine—lung cancer	8.98e-05	0.000479	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Etoposide—lung cancer	8.95e-05	0.000477	CcSEcCtD
Mefloquine—Dyspepsia—Paclitaxel—lung cancer	8.95e-05	0.000477	CcSEcCtD
Mefloquine—Body temperature increased—Cisplatin—lung cancer	8.95e-05	0.000477	CcSEcCtD
Mefloquine—Asthenia—Irinotecan—lung cancer	8.94e-05	0.000477	CcSEcCtD
Mefloquine—Fatigue—Etoposide—lung cancer	8.94e-05	0.000477	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	8.93e-05	0.000476	CcSEcCtD
Mefloquine—Decreased appetite—Paclitaxel—lung cancer	8.84e-05	0.000471	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Paclitaxel—lung cancer	8.78e-05	0.000468	CcSEcCtD
Mefloquine—Fatigue—Paclitaxel—lung cancer	8.76e-05	0.000467	CcSEcCtD
Mefloquine—Asthenia—Gemcitabine—lung cancer	8.71e-05	0.000464	CcSEcCtD
Mefloquine—Confusional state—Docetaxel—lung cancer	8.69e-05	0.000463	CcSEcCtD
Mefloquine—Anaphylactic shock—Docetaxel—lung cancer	8.62e-05	0.000459	CcSEcCtD
Mefloquine—Oedema—Docetaxel—lung cancer	8.62e-05	0.000459	CcSEcCtD
Mefloquine—Pruritus—Gemcitabine—lung cancer	8.59e-05	0.000458	CcSEcCtD
Mefloquine—Feeling abnormal—Etoposide—lung cancer	8.54e-05	0.000455	CcSEcCtD
Mefloquine—Diarrhoea—Irinotecan—lung cancer	8.53e-05	0.000455	CcSEcCtD
Mefloquine—Pneumonia—Doxorubicin—lung cancer	8.48e-05	0.000452	CcSEcCtD
Mefloquine—Gastrointestinal pain—Etoposide—lung cancer	8.48e-05	0.000452	CcSEcCtD
Mefloquine—Shock—Docetaxel—lung cancer	8.48e-05	0.000452	CcSEcCtD
Mefloquine—Nervous system disorder—Docetaxel—lung cancer	8.45e-05	0.00045	CcSEcCtD
Mefloquine—Thrombocytopenia—Docetaxel—lung cancer	8.44e-05	0.00045	CcSEcCtD
Mefloquine—Visual impairment—Methotrexate—lung cancer	8.42e-05	0.000449	CcSEcCtD
Mefloquine—Tachycardia—Docetaxel—lung cancer	8.41e-05	0.000448	CcSEcCtD
Mefloquine—Feeling abnormal—Paclitaxel—lung cancer	8.38e-05	0.000447	CcSEcCtD
Mefloquine—Skin disorder—Docetaxel—lung cancer	8.37e-05	0.000446	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—lung cancer	8.36e-05	0.000446	CcSEcCtD
Mefloquine—Hypersensitivity—Cisplatin—lung cancer	8.34e-05	0.000444	CcSEcCtD
Mefloquine—Gastrointestinal pain—Paclitaxel—lung cancer	8.31e-05	0.000443	CcSEcCtD
Mefloquine—Diarrhoea—Gemcitabine—lung cancer	8.31e-05	0.000443	CcSEcCtD
Mefloquine—Renal failure—Doxorubicin—lung cancer	8.29e-05	0.000442	CcSEcCtD
Mefloquine—Erythema multiforme—Methotrexate—lung cancer	8.26e-05	0.000441	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—lung cancer	8.26e-05	0.000441	CcSEcCtD
Mefloquine—Dizziness—Irinotecan—lung cancer	8.24e-05	0.000439	CcSEcCtD
Mefloquine—Urticaria—Etoposide—lung cancer	8.24e-05	0.000439	CcSEcCtD
Mefloquine—Abdominal pain—Etoposide—lung cancer	8.2e-05	0.000437	CcSEcCtD
Mefloquine—Body temperature increased—Etoposide—lung cancer	8.2e-05	0.000437	CcSEcCtD
Mefloquine—Eye disorder—Methotrexate—lung cancer	8.17e-05	0.000435	CcSEcCtD
Mefloquine—Tinnitus—Methotrexate—lung cancer	8.15e-05	0.000434	CcSEcCtD
Mefloquine—Asthenia—Cisplatin—lung cancer	8.12e-05	0.000433	CcSEcCtD
Mefloquine—Cardiac disorder—Methotrexate—lung cancer	8.11e-05	0.000432	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—lung cancer	8.08e-05	0.000431	CcSEcCtD
Mefloquine—Urticaria—Paclitaxel—lung cancer	8.08e-05	0.000431	CcSEcCtD
Mefloquine—Hypotension—Docetaxel—lung cancer	8.05e-05	0.000429	CcSEcCtD
Mefloquine—Abdominal pain—Paclitaxel—lung cancer	8.04e-05	0.000428	CcSEcCtD
Mefloquine—Body temperature increased—Paclitaxel—lung cancer	8.04e-05	0.000428	CcSEcCtD
Mefloquine—Hepatobiliary disease—Doxorubicin—lung cancer	7.97e-05	0.000425	CcSEcCtD
Mefloquine—Angiopathy—Methotrexate—lung cancer	7.93e-05	0.000423	CcSEcCtD
Mefloquine—Vomiting—Irinotecan—lung cancer	7.92e-05	0.000422	CcSEcCtD
Mefloquine—Mediastinal disorder—Methotrexate—lung cancer	7.88e-05	0.00042	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—lung cancer	7.87e-05	0.000419	CcSEcCtD
Mefloquine—Rash—Irinotecan—lung cancer	7.86e-05	0.000419	CcSEcCtD
Mefloquine—Dermatitis—Irinotecan—lung cancer	7.85e-05	0.000419	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Docetaxel—lung cancer	7.85e-05	0.000418	CcSEcCtD
Mefloquine—Chills—Methotrexate—lung cancer	7.84e-05	0.000418	CcSEcCtD
Mefloquine—Headache—Irinotecan—lung cancer	7.81e-05	0.000416	CcSEcCtD
Mefloquine—Insomnia—Docetaxel—lung cancer	7.79e-05	0.000415	CcSEcCtD
Mefloquine—Diarrhoea—Cisplatin—lung cancer	7.74e-05	0.000413	CcSEcCtD
Mefloquine—Paraesthesia—Docetaxel—lung cancer	7.74e-05	0.000412	CcSEcCtD
Mefloquine—Alopecia—Methotrexate—lung cancer	7.72e-05	0.000412	CcSEcCtD
Mefloquine—Vomiting—Gemcitabine—lung cancer	7.72e-05	0.000412	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—lung cancer	7.7e-05	0.000411	CcSEcCtD
Mefloquine—Dyspnoea—Docetaxel—lung cancer	7.68e-05	0.00041	CcSEcCtD
Mefloquine—Somnolence—Docetaxel—lung cancer	7.66e-05	0.000408	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—lung cancer	7.66e-05	0.000408	CcSEcCtD
Mefloquine—Rash—Gemcitabine—lung cancer	7.65e-05	0.000408	CcSEcCtD
Mefloquine—Dermatitis—Gemcitabine—lung cancer	7.65e-05	0.000408	CcSEcCtD
Mefloquine—Hypersensitivity—Etoposide—lung cancer	7.64e-05	0.000407	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—lung cancer	7.61e-05	0.000406	CcSEcCtD
Mefloquine—Erythema—Methotrexate—lung cancer	7.61e-05	0.000406	CcSEcCtD
Mefloquine—Headache—Gemcitabine—lung cancer	7.61e-05	0.000405	CcSEcCtD
Mefloquine—Dyspepsia—Docetaxel—lung cancer	7.58e-05	0.000404	CcSEcCtD
Mefloquine—Decreased appetite—Docetaxel—lung cancer	7.49e-05	0.000399	CcSEcCtD
Mefloquine—Hypersensitivity—Paclitaxel—lung cancer	7.49e-05	0.000399	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Docetaxel—lung cancer	7.44e-05	0.000397	CcSEcCtD
Mefloquine—Asthenia—Etoposide—lung cancer	7.44e-05	0.000397	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—lung cancer	7.44e-05	0.000397	CcSEcCtD
Mefloquine—Fatigue—Docetaxel—lung cancer	7.43e-05	0.000396	CcSEcCtD
Mefloquine—Nausea—Irinotecan—lung cancer	7.4e-05	0.000395	CcSEcCtD
Mefloquine—Pruritus—Etoposide—lung cancer	7.33e-05	0.000391	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—lung cancer	7.29e-05	0.000389	CcSEcCtD
Mefloquine—Asthenia—Paclitaxel—lung cancer	7.29e-05	0.000389	CcSEcCtD
Mefloquine—Nausea—Gemcitabine—lung cancer	7.21e-05	0.000384	CcSEcCtD
Mefloquine—Vomiting—Cisplatin—lung cancer	7.2e-05	0.000384	CcSEcCtD
Mefloquine—Pruritus—Paclitaxel—lung cancer	7.19e-05	0.000383	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—lung cancer	7.17e-05	0.000382	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—lung cancer	7.16e-05	0.000382	CcSEcCtD
Mefloquine—Rash—Cisplatin—lung cancer	7.14e-05	0.00038	CcSEcCtD
Mefloquine—Dermatitis—Cisplatin—lung cancer	7.13e-05	0.00038	CcSEcCtD
Mefloquine—Feeling abnormal—Docetaxel—lung cancer	7.1e-05	0.000379	CcSEcCtD
Mefloquine—Diarrhoea—Etoposide—lung cancer	7.09e-05	0.000378	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—lung cancer	7.07e-05	0.000377	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—lung cancer	7.06e-05	0.000376	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—lung cancer	7.06e-05	0.000376	CcSEcCtD
Mefloquine—Gastrointestinal pain—Docetaxel—lung cancer	7.05e-05	0.000376	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—lung cancer	7.02e-05	0.000374	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—lung cancer	7.02e-05	0.000374	CcSEcCtD
Mefloquine—Diarrhoea—Paclitaxel—lung cancer	6.95e-05	0.000371	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—lung cancer	6.87e-05	0.000366	CcSEcCtD
Mefloquine—Malaise—Methotrexate—lung cancer	6.86e-05	0.000366	CcSEcCtD
Mefloquine—Dizziness—Etoposide—lung cancer	6.86e-05	0.000365	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—lung cancer	6.84e-05	0.000364	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—lung cancer	6.82e-05	0.000364	CcSEcCtD
Mefloquine—Abdominal pain—Docetaxel—lung cancer	6.81e-05	0.000363	CcSEcCtD
Mefloquine—Body temperature increased—Docetaxel—lung cancer	6.81e-05	0.000363	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—lung cancer	6.81e-05	0.000363	CcSEcCtD
Mefloquine—Chills—Doxorubicin—lung cancer	6.79e-05	0.000362	CcSEcCtD
Mefloquine—Dizziness—Paclitaxel—lung cancer	6.72e-05	0.000358	CcSEcCtD
Mefloquine—Nausea—Cisplatin—lung cancer	6.72e-05	0.000358	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—lung cancer	6.69e-05	0.000357	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—lung cancer	6.63e-05	0.000353	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—lung cancer	6.59e-05	0.000351	CcSEcCtD
Mefloquine—Vomiting—Etoposide—lung cancer	6.59e-05	0.000351	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—lung cancer	6.59e-05	0.000351	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—lung cancer	6.59e-05	0.000351	CcSEcCtD
Mefloquine—Rash—Etoposide—lung cancer	6.54e-05	0.000348	CcSEcCtD
Mefloquine—Dermatitis—Etoposide—lung cancer	6.53e-05	0.000348	CcSEcCtD
Mefloquine—Headache—Etoposide—lung cancer	6.49e-05	0.000346	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—lung cancer	6.48e-05	0.000345	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—lung cancer	6.48e-05	0.000345	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—lung cancer	6.48e-05	0.000345	CcSEcCtD
Mefloquine—Vomiting—Paclitaxel—lung cancer	6.46e-05	0.000345	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	6.43e-05	0.000343	CcSEcCtD
Mefloquine—Rash—Paclitaxel—lung cancer	6.41e-05	0.000342	CcSEcCtD
Mefloquine—Dermatitis—Paclitaxel—lung cancer	6.4e-05	0.000341	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—lung cancer	6.4e-05	0.000341	CcSEcCtD
Mefloquine—Headache—Paclitaxel—lung cancer	6.37e-05	0.000339	CcSEcCtD
Mefloquine—Hypersensitivity—Docetaxel—lung cancer	6.35e-05	0.000338	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—lung cancer	6.33e-05	0.000338	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—lung cancer	6.26e-05	0.000334	CcSEcCtD
Mefloquine—Anaphylactic shock—Methotrexate—lung cancer	6.21e-05	0.000331	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—lung cancer	6.21e-05	0.000331	CcSEcCtD
Mefloquine—Asthenia—Docetaxel—lung cancer	6.18e-05	0.00033	CcSEcCtD
Mefloquine—Nausea—Etoposide—lung cancer	6.16e-05	0.000328	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—lung cancer	6.11e-05	0.000326	CcSEcCtD
Mefloquine—Pruritus—Docetaxel—lung cancer	6.1e-05	0.000325	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—lung cancer	6.09e-05	0.000325	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—lung cancer	6.08e-05	0.000324	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—lung cancer	6.05e-05	0.000323	CcSEcCtD
Mefloquine—Nausea—Paclitaxel—lung cancer	6.04e-05	0.000322	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—lung cancer	6.03e-05	0.000322	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—lung cancer	6e-05	0.00032	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—lung cancer	5.94e-05	0.000317	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—lung cancer	5.92e-05	0.000316	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—lung cancer	5.91e-05	0.000315	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—lung cancer	5.9e-05	0.000314	CcSEcCtD
Mefloquine—Diarrhoea—Docetaxel—lung cancer	5.89e-05	0.000314	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—lung cancer	5.82e-05	0.00031	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—lung cancer	5.8e-05	0.000309	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—lung cancer	5.79e-05	0.000309	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—lung cancer	5.71e-05	0.000304	CcSEcCtD
Mefloquine—Dizziness—Docetaxel—lung cancer	5.7e-05	0.000304	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—lung cancer	5.69e-05	0.000303	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—lung cancer	5.66e-05	0.000302	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—lung cancer	5.62e-05	0.000299	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—lung cancer	5.61e-05	0.000299	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—lung cancer	5.61e-05	0.000299	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—lung cancer	5.61e-05	0.000299	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—lung cancer	5.59e-05	0.000298	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—lung cancer	5.58e-05	0.000297	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	5.57e-05	0.000297	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—lung cancer	5.54e-05	0.000295	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—lung cancer	5.54e-05	0.000295	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—lung cancer	5.52e-05	0.000294	CcSEcCtD
Mefloquine—Vomiting—Docetaxel—lung cancer	5.48e-05	0.000292	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—lung cancer	5.47e-05	0.000291	CcSEcCtD
Mefloquine—Rash—Docetaxel—lung cancer	5.43e-05	0.00029	CcSEcCtD
Mefloquine—Dermatitis—Docetaxel—lung cancer	5.43e-05	0.000289	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—lung cancer	5.42e-05	0.000289	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—lung cancer	5.4e-05	0.000288	CcSEcCtD
Mefloquine—Headache—Docetaxel—lung cancer	5.4e-05	0.000288	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—lung cancer	5.38e-05	0.000287	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—lung cancer	5.38e-05	0.000287	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—lung cancer	5.36e-05	0.000286	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—lung cancer	5.35e-05	0.000285	CcSEcCtD
Mefloquine—Shock—Doxorubicin—lung cancer	5.29e-05	0.000282	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—lung cancer	5.27e-05	0.000281	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—lung cancer	5.26e-05	0.000281	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—lung cancer	5.25e-05	0.00028	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—lung cancer	5.22e-05	0.000278	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—lung cancer	5.2e-05	0.000277	CcSEcCtD
Mefloquine—Nausea—Docetaxel—lung cancer	5.12e-05	0.000273	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—lung cancer	5.12e-05	0.000273	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—lung cancer	5.08e-05	0.000271	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—lung cancer	5.02e-05	0.000268	CcSEcCtD
Mefloquine—Urticaria—Methotrexate—lung cancer	4.93e-05	0.000263	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—lung cancer	4.91e-05	0.000262	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—lung cancer	4.91e-05	0.000262	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—lung cancer	4.9e-05	0.000261	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—lung cancer	4.86e-05	0.000259	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—lung cancer	4.83e-05	0.000257	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—lung cancer	4.79e-05	0.000256	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—lung cancer	4.78e-05	0.000255	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—lung cancer	4.73e-05	0.000252	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—lung cancer	4.67e-05	0.000249	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—lung cancer	4.64e-05	0.000247	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—lung cancer	4.64e-05	0.000247	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—lung cancer	4.58e-05	0.000244	CcSEcCtD
Mefloquine—Asthenia—Methotrexate—lung cancer	4.46e-05	0.000238	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—lung cancer	4.43e-05	0.000236	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—lung cancer	4.4e-05	0.000234	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—lung cancer	4.39e-05	0.000234	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—lung cancer	4.27e-05	0.000228	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—lung cancer	4.25e-05	0.000227	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—lung cancer	4.25e-05	0.000227	CcSEcCtD
Mefloquine—Diarrhoea—Methotrexate—lung cancer	4.25e-05	0.000227	CcSEcCtD
Mefloquine—Dizziness—Methotrexate—lung cancer	4.11e-05	0.000219	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—lung cancer	3.96e-05	0.000211	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—lung cancer	3.95e-05	0.00021	CcSEcCtD
Mefloquine—Rash—Methotrexate—lung cancer	3.92e-05	0.000209	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—lung cancer	3.91e-05	0.000209	CcSEcCtD
Mefloquine—Headache—Methotrexate—lung cancer	3.89e-05	0.000207	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—lung cancer	3.86e-05	0.000206	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—lung cancer	3.8e-05	0.000203	CcSEcCtD
Mefloquine—Nausea—Methotrexate—lung cancer	3.69e-05	0.000197	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—lung cancer	3.68e-05	0.000196	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—lung cancer	3.56e-05	0.00019	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—lung cancer	3.42e-05	0.000182	CcSEcCtD
Mefloquine—Rash—Doxorubicin—lung cancer	3.39e-05	0.000181	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—lung cancer	3.39e-05	0.000181	CcSEcCtD
Mefloquine—Headache—Doxorubicin—lung cancer	3.37e-05	0.00018	CcSEcCtD
Mefloquine—Nausea—Doxorubicin—lung cancer	3.19e-05	0.00017	CcSEcCtD
Mefloquine—BCHE—Metabolism—CYP1A1—lung cancer	9.66e-06	8.2e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KDR—lung cancer	9.64e-06	8.18e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CKB—lung cancer	9.63e-06	8.17e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTA1—lung cancer	9.6e-06	8.15e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ERCC2—lung cancer	9.59e-06	8.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCC3—lung cancer	9.49e-06	8.06e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—UGT1A1—lung cancer	9.47e-06	8.04e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—APOA1—lung cancer	9.29e-06	7.89e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	9.28e-06	7.87e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKR1C1—lung cancer	9.19e-06	7.8e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GNG11—lung cancer	9.13e-06	7.75e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PIK3CA—lung cancer	9.1e-06	7.72e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MDM2—lung cancer	9.06e-06	7.69e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CNDP2—lung cancer	9.05e-06	7.68e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTM2—lung cancer	9.05e-06	7.68e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RAF1—lung cancer	9.03e-06	7.66e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	8.98e-06	7.62e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ERBB2—lung cancer	8.93e-06	7.58e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—UGT1A1—lung cancer	8.92e-06	7.57e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	8.9e-06	7.55e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—APC—lung cancer	8.88e-06	7.54e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KIT—lung cancer	8.88e-06	7.54e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CG—lung cancer	8.88e-06	7.54e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—NRAS—lung cancer	8.88e-06	7.54e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CB—lung cancer	8.82e-06	7.48e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MTOR—lung cancer	8.82e-06	7.48e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTMR3—lung cancer	8.81e-06	7.47e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGF—lung cancer	8.78e-06	7.45e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALDOA—lung cancer	8.69e-06	7.38e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—APOA1—lung cancer	8.64e-06	7.33e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GNG11—lung cancer	8.6e-06	7.3e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PGAM1—lung cancer	8.58e-06	7.28e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—APOA1—lung cancer	8.54e-06	7.25e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—MAPK3—lung cancer	8.51e-06	7.22e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CG—lung cancer	8.49e-06	7.2e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CXCL8—lung cancer	8.47e-06	7.19e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—POMC—lung cancer	8.46e-06	7.18e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NCOA3—lung cancer	8.44e-06	7.16e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—HRAS—lung cancer	8.42e-06	7.14e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—BRAF—lung cancer	8.35e-06	7.09e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—APOA1—lung cancer	8.29e-06	7.04e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6R—lung cancer	8.25e-06	7e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CREBBP—lung cancer	8.24e-06	6.99e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ADCY1—lung cancer	8.21e-06	6.97e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ABCG2—lung cancer	8.21e-06	6.97e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALDOA—lung cancer	8.19e-06	6.95e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2A7—lung cancer	8.19e-06	6.95e-05	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—AKT1—lung cancer	8.18e-06	6.95e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	8.18e-06	6.94e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CASP3—lung cancer	8.11e-06	6.88e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL2—lung cancer	8.1e-06	6.87e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—EGFR—lung cancer	8.09e-06	6.87e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—POMC—lung cancer	8.08e-06	6.86e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL6—lung cancer	8.06e-06	6.84e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HPGDS—lung cancer	8.05e-06	6.83e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ENO2—lung cancer	8.05e-06	6.83e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SDC4—lung cancer	8.01e-06	6.8e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PPP2R1B—lung cancer	8e-06	6.79e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOA3—lung cancer	7.95e-06	6.75e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	7.94e-06	6.74e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—lung cancer	7.89e-06	6.7e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JUN—lung cancer	7.88e-06	6.68e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CREBBP—lung cancer	7.87e-06	6.68e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAP2K1—lung cancer	7.86e-06	6.67e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CD—lung cancer	7.81e-06	6.63e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTT1—lung cancer	7.81e-06	6.63e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CG—lung cancer	7.8e-06	6.62e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCG2—lung cancer	7.74e-06	6.57e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ADCY1—lung cancer	7.74e-06	6.57e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CA—lung cancer	7.74e-06	6.57e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP2A6—lung cancer	7.72e-06	6.55e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GCLC—lung cancer	7.72e-06	6.55e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MMP9—lung cancer	7.66e-06	6.5e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—lung cancer	7.65e-06	6.49e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1A—lung cancer	7.64e-06	6.48e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTEN—lung cancer	7.62e-06	6.47e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ENO2—lung cancer	7.59e-06	6.44e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HPGDS—lung cancer	7.59e-06	6.44e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	7.58e-06	6.43e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CG—lung cancer	7.57e-06	6.43e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PPP2R1B—lung cancer	7.54e-06	6.4e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CD—lung cancer	7.46e-06	6.33e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AKT1—lung cancer	7.43e-06	6.31e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—POMC—lung cancer	7.42e-06	6.3e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ALB—lung cancer	7.36e-06	6.25e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTT1—lung cancer	7.36e-06	6.25e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ENO1—lung cancer	7.32e-06	6.21e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	7.31e-06	6.21e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—RRM1—lung cancer	7.3e-06	6.19e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA3—lung cancer	7.3e-06	6.19e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GCLC—lung cancer	7.27e-06	6.17e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP2A6—lung cancer	7.27e-06	6.17e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EP300—lung cancer	7.27e-06	6.17e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CREBBP—lung cancer	7.23e-06	6.14e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—POMC—lung cancer	7.21e-06	6.12e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SRC—lung cancer	7.07e-06	6e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CA—lung cancer	7.02e-06	5.96e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CREBBP—lung cancer	7.02e-06	5.96e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MDM2—lung cancer	7e-06	5.94e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RAF1—lung cancer	6.97e-06	5.92e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ERBB2—lung cancer	6.9e-06	5.85e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ENO1—lung cancer	6.9e-06	5.85e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—lung cancer	6.88e-06	5.84e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—B4GALT5—lung cancer	6.86e-06	5.82e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CD—lung cancer	6.86e-06	5.82e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	6.84e-06	5.81e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—STAT3—lung cancer	6.81e-06	5.78e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CB—lung cancer	6.81e-06	5.78e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MTOR—lung cancer	6.81e-06	5.78e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NRAS—lung cancer	6.8e-06	5.77e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ALB—lung cancer	6.77e-06	5.74e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA4—lung cancer	6.67e-06	5.66e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CD—lung cancer	6.66e-06	5.65e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ALB—lung cancer	6.57e-06	5.58e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP2E1—lung cancer	6.56e-06	5.57e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL8—lung cancer	6.54e-06	5.55e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MAPK3—lung cancer	6.51e-06	5.52e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA2—lung cancer	6.5e-06	5.52e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CB—lung cancer	6.5e-06	5.52e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—HRAS—lung cancer	6.5e-06	5.52e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NQO1—lung cancer	6.49e-06	5.51e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—lung cancer	6.44e-06	5.47e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MYC—lung cancer	6.33e-06	5.37e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AKT1—lung cancer	6.32e-06	5.36e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA1—lung cancer	6.28e-06	5.33e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CASP3—lung cancer	6.26e-06	5.31e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL2—lung cancer	6.25e-06	5.31e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL6—lung cancer	6.22e-06	5.28e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCC3—lung cancer	6.21e-06	5.27e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EGFR—lung cancer	6.19e-06	5.26e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	6.19e-06	5.25e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP2E1—lung cancer	6.19e-06	5.25e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NQO1—lung cancer	6.12e-06	5.19e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—lung cancer	6.09e-06	5.17e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JUN—lung cancer	6.08e-06	5.16e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKR1C1—lung cancer	6.01e-06	5.1e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CB—lung cancer	5.98e-06	5.07e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—lung cancer	5.92e-06	5.02e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MMP9—lung cancer	5.92e-06	5.02e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1A—lung cancer	5.9e-06	5e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTEN—lung cancer	5.88e-06	4.99e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—STK11—lung cancer	5.85e-06	4.97e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—lung cancer	5.85e-06	4.97e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—UGT1A1—lung cancer	5.83e-06	4.95e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CB—lung cancer	5.8e-06	4.92e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—lung cancer	5.75e-06	4.88e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AKT1—lung cancer	5.74e-06	4.87e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GNG11—lung cancer	5.63e-06	4.77e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTEN—lung cancer	5.62e-06	4.77e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EP300—lung cancer	5.61e-06	4.76e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—STK11—lung cancer	5.51e-06	4.68e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SRC—lung cancer	5.46e-06	4.63e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTP1—lung cancer	5.41e-06	4.59e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CA—lung cancer	5.37e-06	4.56e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—EP300—lung cancer	5.36e-06	4.55e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALDOA—lung cancer	5.36e-06	4.55e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—lung cancer	5.31e-06	4.51e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CAT—lung cancer	5.27e-06	4.47e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—STAT3—lung cancer	5.26e-06	4.46e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NRAS—lung cancer	5.25e-06	4.45e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOA3—lung cancer	5.2e-06	4.41e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—lung cancer	5.2e-06	4.41e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTEN—lung cancer	5.16e-06	4.38e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTP1—lung cancer	5.1e-06	4.33e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ADCY1—lung cancer	5.06e-06	4.29e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCG2—lung cancer	5.06e-06	4.29e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TYMS—lung cancer	5.03e-06	4.27e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK3—lung cancer	5.03e-06	4.27e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTEN—lung cancer	5.01e-06	4.25e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTM1—lung cancer	4.97e-06	4.22e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HRAS—lung cancer	4.97e-06	4.22e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CAT—lung cancer	4.96e-06	4.21e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ENO2—lung cancer	4.96e-06	4.21e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HPGDS—lung cancer	4.96e-06	4.21e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PPP2R1B—lung cancer	4.93e-06	4.18e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—EP300—lung cancer	4.92e-06	4.18e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MYC—lung cancer	4.89e-06	4.15e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCB1—lung cancer	4.83e-06	4.1e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTT1—lung cancer	4.81e-06	4.08e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGFR—lung cancer	4.78e-06	4.06e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—EP300—lung cancer	4.78e-06	4.06e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL6—lung cancer	4.76e-06	4.04e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GCLC—lung cancer	4.76e-06	4.04e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2A6—lung cancer	4.76e-06	4.04e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TYMS—lung cancer	4.74e-06	4.02e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP1A1—lung cancer	4.72e-06	4e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTM1—lung cancer	4.69e-06	3.98e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ERCC2—lung cancer	4.68e-06	3.97e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—lung cancer	4.52e-06	3.83e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ENO1—lung cancer	4.51e-06	3.83e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP1A1—lung cancer	4.44e-06	3.77e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ERCC2—lung cancer	4.41e-06	3.74e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AKT1—lung cancer	4.39e-06	3.73e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CA—lung cancer	4.15e-06	3.52e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—APOA1—lung cancer	4.05e-06	3.43e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2E1—lung cancer	4.04e-06	3.43e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—lung cancer	4.01e-06	3.41e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NQO1—lung cancer	4e-06	3.39e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CA—lung cancer	3.96e-06	3.36e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HRAS—lung cancer	3.84e-06	3.26e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—APOA1—lung cancer	3.81e-06	3.24e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CG—lung cancer	3.69e-06	3.13e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6—lung cancer	3.67e-06	3.12e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CA—lung cancer	3.64e-06	3.09e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—STK11—lung cancer	3.6e-06	3.06e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CA—lung cancer	3.54e-06	3e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—POMC—lung cancer	3.52e-06	2.98e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CG—lung cancer	3.48e-06	2.95e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CREBBP—lung cancer	3.42e-06	2.91e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AKT1—lung cancer	3.39e-06	2.88e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTP1—lung cancer	3.34e-06	2.83e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—POMC—lung cancer	3.31e-06	2.81e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CD—lung cancer	3.25e-06	2.76e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CAT—lung cancer	3.25e-06	2.75e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AKT1—lung cancer	3.24e-06	2.75e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CREBBP—lung cancer	3.23e-06	2.74e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALB—lung cancer	3.21e-06	2.72e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCB1—lung cancer	3.16e-06	2.68e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TYMS—lung cancer	3.1e-06	2.63e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTM1—lung cancer	3.06e-06	2.6e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CD—lung cancer	3.06e-06	2.6e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALB—lung cancer	3.02e-06	2.56e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKT1—lung cancer	2.98e-06	2.53e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP1A1—lung cancer	2.91e-06	2.47e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKT1—lung cancer	2.89e-06	2.45e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ERCC2—lung cancer	2.88e-06	2.45e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CB—lung cancer	2.83e-06	2.4e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—lung cancer	2.8e-06	2.38e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CB—lung cancer	2.67e-06	2.26e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—lung cancer	2.64e-06	2.24e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—APOA1—lung cancer	2.49e-06	2.12e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTEN—lung cancer	2.45e-06	2.08e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—EP300—lung cancer	2.33e-06	1.98e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTEN—lung cancer	2.3e-06	1.96e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CG—lung cancer	2.28e-06	1.93e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—EP300—lung cancer	2.2e-06	1.87e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—POMC—lung cancer	2.17e-06	1.84e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CREBBP—lung cancer	2.11e-06	1.79e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CD—lung cancer	2e-06	1.7e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALB—lung cancer	1.97e-06	1.68e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CB—lung cancer	1.74e-06	1.48e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—lung cancer	1.73e-06	1.47e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CA—lung cancer	1.73e-06	1.46e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CA—lung cancer	1.63e-06	1.38e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTEN—lung cancer	1.51e-06	1.28e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—EP300—lung cancer	1.44e-06	1.22e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKT1—lung cancer	1.41e-06	1.2e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKT1—lung cancer	1.33e-06	1.13e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CA—lung cancer	1.06e-06	9.02e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKT1—lung cancer	8.68e-07	7.37e-06	CbGpPWpGaD
